Exploring and comparing renal adverse effects between PARP inhibitors based on a real-world analysis of post-marketing surveillance data
Although the majority present with reversible creatinine elevation, PARPi-related RAEs merits broader attention, given its potential for clinical consequences. We should strive to early identify those individuals who may have irreversible kidney damage. The focus should be directed toward monitoring renal function in individuals receiving PARPi, especially in senile people and those with a predisposition to AKI.
Authors
- Gang Chen (ORCID: https://orcid.org/0000-0001-9629-8320)
- Lin Jiang (ORCID: https://orcid.org/0000-0003-1204-1865)
- Bin Zhao (ORCID: https://orcid.org/0000-0002-8165-3315)
- Ke Zheng (ORCID: https://orcid.org/0000-0002-4624-0881)
- Sanxi Ai (ORCID: https://orcid.org/0000-0002-9753-955X)
- Chunyu Jia (ORCID: https://orcid.org/0000-0003-0334-0302)
- Yan Qin (ORCID: https://orcid.org/0000-0002-2958-8122)
- Xuemei Li (ORCID: https://orcid.org/0009-0004-2182-9966)
- Xiaohong Fan (ORCID: https://orcid.org/0000-0003-2557-6826)
- Gangan Wang
- Qiuyu Xu
- Jiahui Wang (ORCID: https://orcid.org/0000-0002-7997-7177)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2024-10-18
- DOI
- https://doi.org/10.3389/fmed.2024.1412700
- Citations
- 2
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Bethune Charitable Foundation
- Peking Union Medical College Hospital